, Tracking Stock Market Picks
Enter Symbol:
Rating: SNY

Sanofi-aventis Sa (NYSE: SNY) downgraded to Equal-Weight by Morgan Stanley

Tuesday,  Dec 1, 2015  12:25 PM ET by Betsy O'Brien Harrison

Morgan Stanley downgraded Sanofi-aventis Sa (NYSE: SNY) to Equal-Weight. Previously
Morgan Stanley downgraded to Sanofi-aventis Sa (NYSE: SNY) to Overweight on 10/15/2015, when the stock price was $49.96.

Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. The Company's business includes two main activities: pharmaceuticals and human vaccines through sanofi pasteur. In its pharmaceutical activity, Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. On September 1, 2008, Sanofi-Aventis acquired the Australian company, Symbion CP Holdings Pty Ltd (Symbion Consumer). On September 25, 2008, it acquired Acambis plc. In January 2009, the Company sold its French plant of Colomiers to French pharmaceutical company Unither. In April 2009, the Company acquired Mexican generic company, Laboratorios Kendrick.

Morgan Stanley Investment Research is one of the financial industry's dominant thought leaders in equity and fixed-income investing. Our analysts, economists, and strategists have earned this reputation through timely, in-depth analysis of companies, industries, markets, and the world’s economies. Our teams collaborate to assist Morgan Stanley clients with investment decisions, using cash and derivative instruments across major asset classes and geographies.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy